AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05562492 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CamAPS FX
Description: The automated closed loop system (CamAPS FX) will consist of:~YpsoPump insulin pump (Ypsomed, Burgdorf, Switzerland) Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA) An Android smartphone hosting CamAPS FX app with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump and glucose sensor Cloud upload system to review CGM/insulin data.
Study NCT05562492 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard insulin therapy with CGM
Description: Usual insulin therapy and study CGM.
Study NCT05787379 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Concordant Care Training
Description: Concordant Care training has four components. 1. Clinicians will complete \~3 hours of online, asynchronous training that will teach them practices including validate Veterans' experiences with Long-COVID, develop shared understanding with patients about Long-COVID, and develop patient-centered action plans. Clinicians will be provided with handouts, case examples, video demonstrations, and practice exercises to help them integrate these practices into care. 2. Tele-mentoring groups will be offered \~bi-weekly and be open to all clinician participant in the Concordant Training arm. Content will include review of specific cases, didactics on specific Concordant Care practices, role-play exercises, and review of session recordings. At least two sessions are required. 3. Clinician Pocket Card that serves as a reminder of the Concordant Care process. 4. An electronic prompt will be sent to enrolled Veterans encouraging them to speak with their clinician about their Long-COVID concerns.
Study NCT05787379 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education Packet Training
Description: Clinicians randomized to the control arm will receive a comprehensive information packet with the latest understanding of Long-COVID. Clinicians will also be provided a packet directing them to relevant VA trainings for Long-COVID. Whole Health trainings which focus on wholistic integrated approaches to care will be highlighted. Whole Health is important for all Veterans, and it is thought to be particularly relevant for poorly understood conditions that don't easily fit in traditional medical model.
Study NCT05794191 — intervention group
Intervention type: BIOLOGICAL
Intervention: Vaccine Administration
Description: PCV13 administration
Study NCT05398484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin 25 mgs
Description: One capsule containing 25mg of psilocybin will be administered with water orally. The appearance of psilocybin is Size 2 HPMC opaque.
Study NCT05398484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niacin 100mg
Description: One capsule contains 100mg of niacin will be administered with water orally. The appearance of the active placebo is Size 2 HPMC opaque.
Study NCT05398484 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychotherapy
Description: The manualized psychotherapy platform will consist of 6 hours of preparatory psychotherapy (prior to the single medication session) and 8 hours of integration psychotherapy following the dosing session.
Study NCT05398484 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: The manualized psychotherapy platform will consist of 6 hours of preparatory psychotherapy (prior to the single medication session) and 8 hours of integration psychotherapy following the dosing session.
Study NCT05748405 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Tablets
Study NCT05748405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEF0217
Description: Tablets of 100 mcg AEF0217
Study NCT04971395 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of 2 or 4 mg/kg
Study NCT04971395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XTMAB-16 2 mg/kg
Description: Single dose of 2 mg/kg
Study NCT04971395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XTMAB-16 4mg/kg
Description: Single dose of 4 mg/kg
Study NCT06106945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0305
Description: AZD0305
Study NCT05868525 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 325Mg Tab, Aspirin 81Mg Tab
Description: Patients will be administrated daily oral Aspirin 81 mg or oral Aspirin 325 mg according to their assigned group after randomization.
Study NCT05648773 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Messaging
Description: Booster reminder message
Study NCT05648773 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentive
Description: Financial Incentive for getting boosted within 2-weeks of the message
Study NCT05648773 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment as usual; no additional message and no incentive.
Study NCT04491825 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Skin suction blistering and skin biopsies
Description: Skin suction blistering and skin biopsies will be used for the identification of potential proteomic biomarkers that can distinguish MF from eczema, psoriasis and healthy control skin.
Study NCT04701047 — intervention group
Intervention type: DEVICE
Intervention: vaginal pessary
Description: insertion and follow up of a vaginal pessary
Study NCT06304987 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Long-course chemoradiation and PD-1 inhibitor, with PCSK9 inhibitor
Description: In long-course chemoradiotherapy (CRT) + PD-1 inhibitor for LARC patients, the experimental group used concurrent PCSK9 inhibitor, and the active comparison group did not use PCSK9 inhibitor.
Study NCT06304987 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Long-course chemoradiation and PD-1 inhibitor, without PCSK9 inhibitor
Description: In long-course chemoradiotherapy (CRT) + PD-1 inhibitor for LARC patients, the experimental group used concurrent PCSK9 inhibitor, and the active comparison group did not use PCSK9 inhibitor.
Study NCT05071599 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Twin Arch Brackets
Description: Twin Arch Brackets characterized by double horizontal slots which make it capable to accept two arch wire at the same time which in turn can achieve a better control over orthodontic tooth movement
Study NCT04701047 — intervention group
Intervention type: PROCEDURE
Intervention: Vaginal prolapse surgery
Description: surgery and follow up after vaginal prolapse surgery
Study NCT05694780 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep intervention
Description: Standard obstetric care plus the sleep intervention which is a 8-week program based on sleep hygiene education and cognitive-behavioral training.
Study NCT05823233 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold application+Deep friction+Home exercise+Eccentric stretching
Description: In our study, deep friction massage will be performed by the researcher with the tip of the thumb, maintaining the pressure for 3-5 minutes in the posterior direction to the tenoosseous junction. The application will be performed 3 times a week for a total of 12 sessions for 4 weeks. After the deep friction massage, cold application will be made for 15 minutes. Simultaneously with the electrical stimulation of the affected arm, the patient will be asked to stretch for 5 seconds and rest for 5 seconds, and doing this 15 times will be considered 1 set. After 1 minute of rest, he will be asked to do this practice for 2 more sets, so 3 sets of 15 repetitions will be completed in total. A total of 12 sessions will be applied 3 days a week for 4 weeks. In our study, a home exercise program consisting of passive stretching and strengthening (concentric and eccentric) exercises will be applied.
Study NCT05823233 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold application+Deep friction+Home exercise
Description: In our study, deep friction massage will be performed by the researcher with the tip of the thumb, maintaining the pressure for 3-5 minutes in the posterior direction to the tenoosseous junction. The application will be performed 3 times a week for a total of 12 sessions for 4 weeks. After the deep friction massage, cold application will be made for 15 minutes. In our study, a home exercise program consisting of passive stretching and strengthening (concentric and eccentric) exercises will be applied.
Study NCT04769193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adipeau face cream
Description: Adipeau face cream contains the natural actives Carthamus Tinctorius (Safflower) Seed Oil and Kaempferia Parviflora Rhizome Extract (Black Ginger).
Study NCT04848064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT04848064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study NCT04848064 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mogamulizumab
Description: Given IV
Study NCT04848064 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Natural Killer Cell Therapy
Description: Given via infusion
Study NCT04848064 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04848064 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05994235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Description: Mosunetuzumab will be administered in weekly dose increments (step-up dosing) during Cycle 1 and then on Day 1 of each cycle. Mosunetuzumab will be given in 28-day cycles for up to 12 cycles. Mosunetuzumab will be administered SC at the dose of 5 mg on Day 1, 45 mg on Day 8, and 45 mg on Day 15 in Cycle 1. Beginning with Cycle 2, it will be administered SC at the dose of 45 mg on Day 1. Each cycle lasts 4 weeks.
Study NCT05994235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat Pill
Description: Oral tazemetostat will be administered by mouth twice daily at standard dosing (800 mg twice daily) beginning at the same time as mosunetuzumab initiation until disease progression, unacceptable toxicity, or consent is withdrawn. Patients will remain on tazemetostat for up to twelve 28-day cycles from initiation of mosunetuzumab.
Study NCT05118919 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BGP-014
Description: Oral capsule containing lyophilised Lactobacillus reuteri
Study NCT05118919 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsule
Study NCT06557265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKX019
Description: NKX019 is an investigational allogeneic CD19-Directed CAR NK
Study NCT06557265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepletion
Study NCT05954780 — intervention group
Intervention type: DRUG
Intervention: Selinexor
Description: Selinexor/bortezomib/dexamethasone according to Nexpovio® SmPC
Study NCT05293587 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Physical activity sessions will take place 3x/week over six weeks and will take between 45 and 60 minutes for each session. The sessions will be led by a Serenity Behavioral Health CPS as part of the PEERS program and will be supervised by research staff. Sessions will occur at public parks. Transportation to the park will be provided by Serenity Behavioral Health. Structured activities will include a warm-up, a mix of simple exercises requiring minimal supplies (such as walking, basic aerobic movements, and body weight resistance exercises), and cool-down. Sessions will be held in green park environments with shade, restrooms, and level walking paths.
Study NCT04949867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon
Description: Glucagon is filled in the pump and given automatically in case of hypoglycemia or pending hypoglycemia.
Study NCT04949867 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Closed-loop System
Description: Closed-loop system comprise of two DANA RS (R) insulin pumps (FiAsp-GlucaGen vs FiAsp-saline), one DexCom G6 sensor, and a smartphone for the control algorithm.
Study NCT04949867 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Closed-loop System
Description: Closed-loop system comprise of two DANA RS (R) insulin pumps (FiAsp-GlucaGen vs FiAsp-saline), one DexCom G6 sensor, and a smartphone for the control algorithm.
Study NCT05903599 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation
Description: The size of both electrodes will be 5cm x 5cm placed on the head with the anode on the primary motor cortex M1 of the affected side while the cathode on the contralesional eye. The duration of the stimulation of anodal TDCS is 20 min and the intensity of current will be 2mA. The ramp up and down period will be 30se each. Treatment duration will be 5 times a week for 6 weeks for postural stability.
Study NCT05903599 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Description: postural training by visual feedback and weight shifting towards the non-paretic side. This program will have two phases. Phase one have 4 stages; The first stage (sessions 1-7), second stage (sessions 8-14), third stage (sessions 15-22), fourth stage (sessions 23-30).~Next phase will include the exercises including balancing exercises.
Study NCT04885881 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ozone therapy
Description: Patients in the ozone therapy group will be treated with ozone (O2-O3) in a volume of 5 ml and a dose of 10 µg / ml for three consecutive weeks in a weekly session to the most painful trigger point.
Study NCT04885881 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine injection group
Description: Patients in the lidocaine injection group will be applied to the most painful trigger point in a volume of 2 ml of 1% lidocaine for three consecutive weeks, once a week.
Study NCT05541003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBT-NM108
Description: All patients will consume NBT-NM108 in the form of 2 muffins daily.
Study NCT05885763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Difelikefalin Injection
Description: Participants receive Difelikefalin three times a week (0,5 micrograms/kg dry body weight). Difelikefalin is administered by intravenous bolus injection into the venous line of the dialysis circuit at the end of each dialysis.
Study NCT04817124 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Description: Anodal transcranial direct current stimulation (tDCS), 6 sessions with 20 minutes stimulation each (1,5 mA).
Study NCT04817124 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Intensive cognitive training
Description: Intensive cognitive training of a letter memory updating task, 6 sessions for approximately 20 min
Study NCT04817124 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive cognitive training
Description: Intensive cognitive training of a letter memory updating task, 6 sessions for approximately 20 min
Study NCT04817124 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Sham transcranial direct current stimulation (tDCS), 6 sessions with 30 sec stimulation each (1,5 mA) to ensure blinding of participants.
Study NCT04846712 — intervention group
Intervention type: OTHER
Intervention: Collect data of medical record
Description: Collect data of medical record: initial physical examination, ultrasound (US), Magnetic Resonance Imaging (MRI), physical examination at 30 days, physical examination at 3 months, physical examination at 6 months and final examination at 12 months.
Study NCT05537142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BV100
Description: Rifabutin for Infusion
Study NCT06526793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0486
Description: Investigational Product administered via intravenous infusion.
Study NCT05395026 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electrical stimulation of vagus nerve
Description: VNS electrical stimulation parameters (pulse duration, pulse amplitude, and pulse frequency) will be systematically changed to determine the effect on vagus nerve activation, laryngeal muscle contraction, and heart rate.
Study NCT06529393 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SHAC block
Description: with the patient in a beach-chair position and with the arm in extension, the subscapularis muscle is stretched posteriorly and becomes easily visible. With external rotation and abduction, the coracobrachialis and the biceps brachii muscles are displaced, allowing the visualization of the interfascial space between the deep lamina of the deltoid muscle fascia and the superficial lamina of the subscapularis fascia.Once the injection into the fascial space is achieved, the investigators can proceed towards the glenohumeral pericapsular space by crossing the subscapularis muscle with the needle. By injecting the pericapsular space, the investigators reach the terminal articular branches indistinctly from their origin. Furthermore, through the Weitbrecht foramen, a natural capsular foramen between the upper and middle glenohumeral ligaments, the investigators also reach the intra-articular space .
Study NCT06529393 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: suprascapular nerve block
Description: Patients will be placed in lateral position by using A high - frequency linear ultrasound probe will be placed approximately 2 cm medial to the medial border of the acromion and about 2 cm cranial to the superior margin of the scapular spine until supraspinatus or infraspinatus muscle contractions were elicited. Following negative aspiration,A 21G 10-cm needle will be inserted using an in-plane approach .The tip of the needle will be placed at the floor of the supraspinatus fossa where the nerve has passed .A volume of 15 mL of a mixture of 2% lidocaine (5 mL) and 0.5% levobupivacaine (10 mL) was injected.
Study NCT05400837 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Corrie Virtual Atrial Fibrillation Management Program
Description: Intervention aims to implement guideline-recommended Afib care
Study NCT06530563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oliceridine Injection [Olinvyk]
Description: Oliceridine fumarate injection, specifications: 1mg/1mL, 2mg/2 mL, 10mg/10 mL; Stored in the dark, 15-30 ℃, not frozen; Jiangsu Nhwa pharmaceutical co., LTD. Production.
Study NCT06530563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oliceridine Injection [Olinvyk]
Description: Oliceridine fumarate injection, specifications: 1mg/1mL, 2mg/2 mL, 10mg/10 mL; Stored in the dark, 15-30 ℃, not frozen; Jiangsu Nhwa pharmaceutical co., LTD. Production.
Study NCT06530563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil Citrate
Description: Sufentanil Citrate injection, specification: 50 ug/ml, 1 ml; Avoid light seal; Yichang humanwell pharmaceutical co., LTD.
Study NCT06530563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil Citrate
Description: Sufentanil Citrate injection, specification: 50 ug/ml, 1 ml; Avoid light seal; Yichang humanwell pharmaceutical co., LTD.
Study NCT06527495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib Tablets (200 -400 mg) twice daily
Study NCT05910710 — intervention group
Intervention type: GENETIC
Intervention: Visium, Whole Genome Sequencing(WGS)/Whole Transcriptome Sequencing(WTS)
Description: Visium : Spatial transcriptomics WGS/WTS : detection of somatic mutation
Study NCT06391905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCSK9 inhibitor in combination with standard advanced first-line regimen group
Description: Fluorouracil and platinum as the base chemotherapy regimen, with or without targeted therapy, was administered subcutaneously at a fixed dose of 150 mg of PCSK9 inhibitor every two weeks starting on day 1 of patient enrollment
Study NCT06391905 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: standard advanced first-line regimen group
Description: Fluorouracil and platinum were used as the basic chemotherapy regimens, with or without targeted therapy, and no additional injection of PCSK9 inhibitors
Study NCT05703555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tusamitamab ravtansine
Description: Eligible subjects will receive Tusamitamab ravtansine (100mg/m2 IV Q2W). Subjects without evidence of disease progression or drug related toxicity can continue treatment with Tusamitamab ravtansine (100 mg/m2 IV Q2W) until disease progression, unacceptable toxicity occurs, or the participant's or Investigator's decision to stop the treatment.
Study NCT05928728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Colchicine 0.5 mg once daily
Study NCT05928728 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily
Study NCT05447585 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coronary atherectomy system of Shanghai MicroPort Rhythm
Description: Coronary Atherectomy System utilizes a diamond-coated eccentric crown to expand the lumen diameter via centrifugal forces while rotating over an atherectomy guide wire.
Study NCT05447585 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rotablator Rotational Atherectomy System
Description: The Rotablator Rotational Atherectomy System is comprised of a Rotablator RotaGlide, a Rotablator RotaLink Plus/RotaWire/Console
Study NCT06463938 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator
Description: CPP-ACP paste will be applied on exposed area